SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN® (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria™ from Novartis. According to investigators, ZADAXIN treatment given with the H1N1 vaccine led to a statistically significant (p value=0.04) increase in the percentage of subjects who seroconverted, also when evaluated 42 days after vaccination, compared to those who received the H1N1 vaccine alone…

Go here to see the original: 
SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine

You may also like:

• Stats To Watch: Flu Affects 1 To 4 Percent Of Americans On Any Given Day
• Teen Vaccination Rates Increasing Across The US
• Study Examines Heat Related Illness In High School Athletes
• FDA Approves Strativa Pharmaceuticals’ Zuplenz® (ondansetron) Oral Soluble Film
• Study Demonstrates That IRIDEX MicroPulse Laser Effectively Treats Eyes With Diabetic Macular Edema
• Don’t Let Cupid’s Arrows Make Your Eyes Water, With New Guide To Passionate Safer Sex From THT, UK
• UGL Unicco First To Embrace Ionator EXP Ionized Water Cleaner That Kills H1N1 Virus
• UCSD Nanoengineering Discovery Could Lead To Enhanced Electronics
• Researchers Find New Patterns In H1N1 Deaths
• Pollution Linked To Hospitalizations For Pneumonia In Older Adults